Futura Medical
is the developer of innovative sexual health products, including lead product Eroxon®. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Our purpose is to enhance our patients and consumers’ quality of life to enable them to enjoy their lives to the full.
Share Price
Eroxon®
Lead product MED3000, is the only fast-acting topical clinically proven treatment for erectile dysfunction available without prescription in Europe.
MED3000 which utilises our proprietary DermaSys® technology is a topically applied gel developed specifically for the treatment of erectile dysfunction (ED).
Our Products
Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain. Our late stage pipeline of products is based on our proprietary, transdermal DermaSys® technology designed to offer rapid and targeted local delivery of clinically proven effective treatments via the skin.
TPR100
TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.
Investor Centre
Our investor centre includes all key investor information such as corporate documents, share price chart and the information required pursuant to AIM Rule 26.
Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.
Our Strategy
Current therapeutic areas are sexual health and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst seeking to minimise risk.